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Abstract 
Objectives: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive 
neurodegenerative disease of motor neurons with a median survival of 2 years. Familial 
ALS has a younger age of onset than apparently sporadic ALS. We sought to determine 
whether this younger age of onset is a result of ascertainment bias, or has a genetic 
basis. 
Methods: Samples from people with ALS were sequenced for thirteen ALS genes. To 
determine the effect of genetic variation, age of onset was compared in people with 
sporadic ALS carrying a pathogenic gene variant and those not; to determine the effect 
of family history, we compared those with genetic sporadic ALS and familial ALS. 
Results: There were 941 people with a diagnosis of ALS, 100 with familial ALS. Of 
841 with apparently sporadic ALS, 95 carried a pathogenic gene variant. Mean age of 
onset in familial ALS was 5.3 years younger than for apparently sporadic ALS (p = 6.0 
x 10-5, 95% CI 2.8-7.8 years). Mean age of onset of genetic sporadic ALS was 2.9 years 
younger than non-genetic sporadic ALS (p = 0.011, 95% CI 0.7-5.2 years). There was 
no difference between the mean age of onset in genetic sporadic ALS and familial ALS 
(p = 0.097). 
Conclusions: People with familial ALS have an age of onset about 5 years younger 
than those with apparently sporadic ALS and we have shown that this is a result of 
Mendelian gene variants lowering the age of onset, rather than ascertainment bias.  
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Introduction 
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is a rapidly 
progressive and paralysing illness resulting from degeneration of upper and lower motor 
neurons; it has no cure and the median survival is 2 years.1 The mean age of onset in 
clinic populations is about 58 years,2 and in population studies about 64,3 but it can 
affect people of any age. 
 
The age of onset of people with familial ALS is widely reported as being about 10 years 
younger than for those with apparently sporadic ALS.4-6 This may be a result of the 
greater awareness of those who have already experienced ALS in their family leading 
them to seek medical attention sooner, and the greater likelihood of recognition of the 
diagnosis by medical professionals when there is an existing family history. Such 
ascertainment bias has been proposed as the mechanism for the genetic phenomenon of 
anticipation, in which genetic diseases seem to occur at younger ages in succeeding 
generations.7 Another explanation, however, is that large effect Mendelian ALS genes 
themselves lower the disease age of onset. Studies aiming to investigate genetic factors 
that influence ALS phenotypes, including age of onset, have yet to yield replicable 
positive results.8  
 
Familial ALS has been described since the mid-1800s, and the rate is reported as 5%,9 
10%,10 or as high as 20%.11 The reasons for the discrepancy probably relate, at least in 
part, to differing personal definitions of a positive family history.12 People with ALS but 
without a family history are described as having sporadic or isolated ALS. Sporadic 
ALS is sometimes conflated with non-genetic ALS, but familial ALS may be missed, 
for example, because of the uncertainty around what should constitute a relevant family 
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history, and apparently sporadic ALS may sometimes result from large effect, rare, 
Mendelian gene variants.13-15 The result is that there are three genetic groups of people 
with ALS: those with a family history of disease (group 1), those with no family history 
but a known genetic cause (group 2), and those with no family history and no known 
genetic cause (group 3). The relative age of onset would be expected to differ between 
these groups depending on whether ascertainment bias or genetic effects are driving the 
earlier onset. If ascertainment bias is the explanation for a younger age of onset in 
familial ALS, group 1 should have a younger age of onset than group 2, because the 
only difference is knowledge of family history (both share a genetic basis), whereas if 
genetic causes are the explanation, group 2 should have a younger age of onset than 
group 3, because the only difference is a genetic basis of disease (in both there is no 
known family history).  
 
We therefore sought to determine whether the younger age of onset observed in those 
with familial ALS is a result of ascertainment bias. 
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Methods 
Data sources 
Patients of European ancestry who had contributed to the UK National DNA Bank for 
Motor Neuron Disease Research were analysed under ethical approval reference 
08/H0405/60. Age of onset and family history were obtained for each person. 
 
Determination of pathogenic ALS gene variants 
A panel of thirteen ALS genes was tested (ANG, C9orf72, DAO, DCTN1, FUS, OPTN, 
PFN1, SOD1, SQSTM1, TARDBP, UBQLN2, VAPB, and VCP), selected for harbouring 
large effect, rare, Mendelian ALS gene variants.16 17 Pathogenicity was defined based on 
previously reported association with ALS, or detection in cases, but not in controls or 
several control databases.17 Because of the rapid rate of advance of ALS genetics, more 
recently identified genes, such as TBK1, were not studied.18 DNA was sequenced using 
Illumina MiSeq technology by means of the Illumina TruSeq Custom Amplicon Assay, 
as previously described,17 and repeat primed PCR used to assay the hexanucleotide 
repeat expansion in the C9orf72 gene.19 
 
Patients were classified into three groups: Group 1, familial ALS; Group 2, apparently 
sporadic ALS with a genetic basis; Group 3, apparently sporadic ALS without an 
identified genetic basis. 
 
Statistical analysis 
Mean age of onset between groups was compared with a t-test. Uncorrected p-values are 
reported. To estimate the size of any ascertainment bias observed, the median time 
between symptom onset and diagnosis was compared between those with familial ALS 
7 
 
and those with apparently sporadic ALS, in a Mann Whitney U test. Analyses were 
performed in SPSS V.24.0. 
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Results 
There were 941 people with ALS included in the study, 841 with apparently sporadic 
ALS and 100 with familial ALS (Table 1). There were 95 people with apparently 
sporadic ALS with a presumed pathogenic ALS gene variant (Table 2), and 746 
without.  
 
The mean age of onset for those with familial ALS was 56.2 years (SD 12.1), all 
apparently sporadic ALS 61.5 years (SD 11.0), genetically determined apparently 
sporadic ALS 58.9 years (SD 10.3), and apparently sporadic ALS without a genetic 
basis 61.8 years (SD 11.1).  
 
Mean age of onset in familial ALS was 5.3 years younger than for apparently sporadic 
ALS (p = 6.0 x 10-5, 95% CI for the difference 2.8-7.8 years), confirming previous 
observations that familial ALS has a younger age of onset.  
 
There was no difference between the mean age of onset of people with familial ALS 
(group 1) and those with genetic apparently sporadic ALS (group 2; p = 0.097), 
suggesting that ascertainment bias plays little role in the observed younger age of onset. 
The mean age of onset of those with genetic apparently sporadic ALS (group 2) was 2.9 
years younger than those with non-genetic sporadic ALS (group 3; p = 0.011, 95% CI 
for the difference 0.7-5.2 years), consistent with the hypothesis that genetic burden 
lowers the age of onset. Combining the genetic groups and comparing them with the 
non-genetic ALS group confirmed the finding, with a mean age of onset 3.4 years 
younger for the genetic groups than the non-genetic group (p = 2.0 x 10-6, 95% CI for 
the difference 2.5-6.1). 
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Median time between symptom onset and diagnosis was 3 months shorter for familial 
ALS than apparently sporadic ALS (p = 0.012). 
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Discussion 
We have confirmed that people with familial ALS have an age of onset about 5 years 
younger than those with apparently sporadic ALS, as opposed to the widely quoted 10 
years, and we propose that this up-to-date figure obtained from a large dataset should be 
utilised in the clinical setting, particularly when communicating with patients. We have 
shown that this younger age of onset in familial ALS is a result of Mendelian gene 
variants lowering the actual age of onset, rather than ascertainment bias resulting in 
quicker recognition of symptoms. Ascertainment bias does exist, in that people with a 
family history of ALS are diagnosed on average 3 months more quickly than those 
without, but the ascertainment bias has no effect on age of onset. 
 
Our findings are consistent with recent findings in which the multistep model of ALS20 
was applied to three known genetic causes of ALS: mutation in SOD1, mutation in 
TARDBP (coding for TDP43), and pathological expansion of a hexanucleotide repeat in 
the C9orf72 gene.21 These gene variants account for more than one step in the 
pathological process leading to ALS, leaving fewer risk factors to encounter before 
onset and therefore making a younger age of onset more likely. One might also expect 
some genes or gene variants to show a characteristic spectrum of age of onset, which 
will become apparent as our genetic knowledge of ALS increases. A similar situation 
may also exist in other neurodegenerative diseases in which those with a family history 
have a younger onset than those without, such as Alzheimer’s disease and Parkinson’s 
disease. 
 
A weakness of this study is that we only ascertained a genetic basis for ALS using a 
panel of thirteen genes. Even with this restricted set, however, we were able to show 
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that the reduced age of onset is a result of Mendelian disease genes. Furthermore, it is 
only now, with the availability of high throughput gene sequencing, that a study like 
this is possible, since the prospect of sequencing a panel of thirteen genes in more than 
900 people would not have been feasible a few years ago. 
 
Genetic modulators of the age of ALS onset have been studied before,8 22-27 but not 
replicated. The explanation for why these have not been replicated may be that genetic 
risk factors themselves lower the age of onset and other genetic variants that do not 
influence risk have only a limited effect on age of onset, making them difficult to detect, 
even with large sample sizes.  
 
Although we have identified this genetic effect on age of onset using large effect, rare 
variants, the liability threshold model of disease28 29 would suggest that all genetic 
contributors to ALS risk lower age of onset, even common variants that have a small 
effect on risk. In the liability threshold model, there is a normal distribution of the 
burden of genetic and environmental risk factors (liabilities) across the population. Most 
individuals who are unaffected will possess some degree of liability, however only 
individuals with a burden of risk factors sufficient to cross a threshold develop disease. 
A consequence of the model is that affected individuals with the least at-risk phenotype 
are also those with a higher liability than average, since the threshold must be higher for 
a low risk phenotype (that is why it is low risk), and yet they still have sufficient burden 
to cross it. One of the strongest risk factors for ALS is increased age, and, therefore, 
younger patients must carry a higher burden of risk factors. Thus, genetic burden is 
likely to be higher in younger patients, and, conversely, the age of onset will be lower in 
those with a higher genetic burden. One study has shown that people with ALS 
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harbouring variants in more than one gene had a disease onset 10 years earlier than 
those with variants identified in only one gene, supporting the idea that genetic burden 
influences age of onset.30 
 
Our findings show that Mendelian gene variants are associated with a younger age of 
onset in ALS, regardless of family history. Further studies are needed to elucidate the 
mechanisms by which this occurs. 
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Tables 
Gene Variant Number of cases 
C9orf72 Expansion mutation 34 
DAO p.R199W 1 
FUS p.R521H 2 
 p.R514G 1 
SOD1 p.C112Y 1 
 p.D91A 1 
 p.L107F 1 
 p.D102N 1 
 p.D102G 1 
 p.I114T 2 
 p.D77Y 2 
SQSTM1 p.K238E 2 
TARDBP p.N378D 2 
 p.A90V 1 
 p.M337V 1 
 p.G348V 1 
 p.Y374X 1 
UBQLN2 p.P497H 1 
No mutation identified  44 
Total  100 
 
Table 1. Mutations identified in those with familial ALS. 95 of the 100 familial ALS 
cases were tested for the C9orf72 expansion mutation. 
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Gene Variant Number of cases 
ANG  p.K78E* 2 
 
p.R146H 1 
C9orf72 Expansion mutation* 36 
DAO p.R199Q 1 
DCTN1 p.V1081M 1  
p.T12A 1  
p.R785W 1 
FUS p.R269W 1  
p.R521C 1  
p.P431L 1  
p.R521L 1  
p.G507D 1 
 
p.221_221del 1 
OPTN p.R545Q 1 
 
Exon 7/Intron 7 splice site 1 
 
p.Q441X 1  
p.E380fs 1  
p.V295F 1  
p.N303K 1  
p.G509R 1 
 p.A184V* 1 
 p.K413fs* 1  
p.R271H* 1  
p.F226S 1 
PFN1 p.E117D* 1 
 p.E117G* 1 
SOD1 p.D91A 1 
 
p.T40A* 1  
p.S135G* 1  
p.I114T 2  
p.L9V 1 
SQSTM1 p.K238E* 7  
p.P392L* 2 
TARDBP p.G287S* 3  
p.A90V 1 
UBQLN2 p.A603D 1 
 
p.T334M 3 
 
p.L87F 1 
 
p.P497H 1 
 
p.496_499del 1 
VAPB p.158_159del* 7  
p.M170I* 5  
p.R184Q 1 
VCP p.I114V 1  
p.G523V 1 
18 
 
Total 
 
103 variants (95 people) 
 
Table 2. Mutations identified in those with apparently sporadic ALS. In some cases, an 
individual had more than one pathogenic gene variant; such cases are indicated by an 
asterisk and counted for each variant. Three of these had C9orf72 expansion as one of 
the variants.  
